Revolutionary Gadget Poised to Simplify Vision-Saving Treatments
New Surgical Tool Shows Promise in Gene and Cell Therapy Clinical Trials at Penn Vet
A team of vision scientists from the Division of Experimental Retinal Therapies at Penn Vet has conducted a new study that demonstrates the use of a novel surgical tool in gene and cell therapy clinical trials. The study, led by William A. Beltran, was part of ongoing trials at Penn Vet and was recently published and presented at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting.
The novel surgical tool, which has been previously used in gene and cell therapy clinical trials at Penn Vet, allows for the placement of therapies directly beneath the retina. This minimally invasive approach could potentially improve outcomes for patients undergoing such trials.
The study involved a team that has been involved in gene and cell therapy clinical trials at Penn Vet. They used the tool to place therapies under the retina, a method that has shown promising results. The authors of the latest study, however, are not explicitly mentioned in the provided search results.
The approach used by the tool is minimally invasive, making it an attractive option for gene and cell therapy procedures. The study's findings suggest that the use of the novel surgical tool in gene and cell therapy clinical trials at Penn Vet is promising.
In the study, the team conducted gene and cell therapy clinical trials using the novel surgical tool. The tool was previously used in such trials, but this is the first time it has been used at Penn Vet. The study was conducted by a team from Penn Vet, and the findings indicate that the minimally invasive approach could potentially improve outcomes for patients undergoing gene and cell therapy clinical trials at Penn Vet.
While the authors of the latest study are not explicitly mentioned, the study was conducted by a team involved in gene and cell therapy clinical trials. The study was conducted by a team from Penn Vet, led by William A. Beltran, and it demonstrates the use of the novel surgical tool in gene and cell therapy clinical trials at Penn Vet. The study's findings suggest that the use of the novel surgical tool in gene and cell therapy clinical trials is promising and could potentially improve outcomes for patients.
